Ann: FDA RPD Designation Granted for RC220 Bisantrene, page-81

Not sure if this has been mentioned before. FTO expression tends to form during childhood and plateau as an adult. Happy to be corrected.

This is interesting in hindsight with the 2 children cured of AML. With the possibility of a paediatric AML trial, does FTO inhibition provide additional benefits?

Also, paediatric patients are more sensitive to cardiotoxicity than adults.

Has Dr Sabnis picked up on these two key points plus the fact that Bisantrene is a Trojan horse against EMD AML.

Expecting an investigator sponsor trial inbound soon!